Epigenetic silencing of ARRDC3 expression in basal-like breast cancer cells

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Soung, Young Hwa ^a   Pruitt, Kevin ^b   Chung, Jun ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARRDC3 PROTEIN, HUMAN; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; MESSENGER RNA; RETINA S ANTIGEN;

ACETYLATION; APOPTOSIS; BREAST NEOPLASMS; CARCINOMA, BASAL CELL; CELL MOTION; CELL PROLIFERATION; CHEMISTRY; CHROMATIN IMMUNOPRECIPITATION; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; HUMAN; METABOLISM; PATHOLOGY; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ACETYLATION; APOPTOSIS; ARRESTINS; BLOTTING, WESTERN; BREAST NEOPLASMS; CARCINOMA, BASAL CELL; CELL MOVEMENT; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; PROMOTER REGIONS, GENETIC; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 84893134871     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep03846     Document Type: Article

References (40)

1. Lin, S. X. et al.Molecular therapy of breast cancer: progress and future directions. Nat Rev Endocrinol. 6, 485-493 (2010)
2. Da Silva, L.& Lakhani, S. R. Pathology of hereditary breast cancer. Mod Pathol. 23 Suppl 2, S46-51 (2010)
3. Carey, L. A. Through a glass darkly: advances in understanding breast cancer biology, 2000-2010. Clin Breast Cancer. 10, 188-195 (2010)
4. Prat, A. & Perou, C. M. Deconstructing the molecular portraits of breast cancer. Mol Oncol. 5, 5-23 (2011)
5. Goodison, S., Sun, Y. & Urquidi, V. Derivation of cancer diagnostic and prognostic signatures from gene expression data. Bioanalysis. 2, 855-862 (2010)
6. Venkitaraman, R. Triple-negative/basal-like breast cancer: clinical, pathologic and molecular features. Expert Rev Anticancer Ther. 10, 199-207 (2010)
7. Seal, M. D. & Chia, S. K. What is the difference between triple-negative and basal breast cancers? Cancer J. 16, 12-16 (2010)
8. Toft, D. J. & Cryns, V. L. Minireview: Basal-like breast cancer: from molecular profiles to targeted therapies. Mol Endocrinol. 25, 199-211 (2011)
9. Haupt, B., Ro, J. Y. & Schwartz, M. R. Basal-like breast carcinoma: a phenotypically distinct entity. Arch Pathol Lab Med. 134, 130-133 (2010)
10. Isakoff, S. J. Triple-negative breast cancer: role of specific chemotherapy agents. Cancer J. 16, 53-61 (2010)
11. Ismail-Khan, R. & Bui, M. M. A review of triple-negative breast cancer. Cancer Control. 17, 173-176 (2010)
12. de Ruijter, T. C. et al. Characteristics of triple-negative breast cancer. J Cancer Res Clin Oncol. 137, 183-192 (2011)
13. Carey, L. et al. Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol. 7, 683-692 (2010)
14. Bosch, A. et al. Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research. Cancer Treat Rev. 36, 206-215 (2010)
15. Charafe-Jauffret, E. et al. Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene. 25, 2273-2284 (2006)
16. Adelaide, J. et al. Integrated profiling of basal and luminal breast cancers. Cancer Res. 67, 11565-11575 (2007)
17. Turner, N. et al. Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene. 29, 2013-2023 (2010)
18. Baylin, S. B. & Ohm, J. E. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer. 6, 107-116 (2006)
19. Yang, X. J. & Seto, E. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene. 26, 5310-5318 (2007)
20. Peserico, A. & Simone, C. Physical and functional HAT/HDAC interplay regulates protein acetylation balance. J Biomed Biotechnol. 2011, 371832 (2011)
21. Vaissiere, T., Sawan, C. & Herceg, Z. Epigenetic interplay between histone modifications and DNA methylation in gene silencing. Mutat Res. 659, 40-48 (2008)
22. Taylor, D. M.,Maxwell, M. M., Luthi-Carter, R. & Kazantsev, A. G. Biological and potential therapeutic roles of sirtuin deacetylases. Cell Mol Life Sci. 65, 4000-4018 (2008)
23. Daitoku, H. et al. Silent information regulator 2 potentiates Foxo1-mediated transcription through its deacetylase activity. Proc Natl Acad Sci U S A. 101, 10042-10047 (2004)
24. Rothgiesser, K. M. et al. SIRT2 regulates NF-kappaB dependent gene expression through deacetylation of p65 Lys310. J Cell Sci. 123, 4251-4258 (2010)
25. North, B. J. et al. The human Sir2 ortholog, SIRT2, is an NAD1-dependent tubulin deacetylase. Mol Cell. 11, 437-444 (2003)
26. Jin, Y. H. et al. Sirt2 interacts with 14-3-3 beta/gamma and down-regulates the activity of p53. Biochem Biophys Res Commun. 368, 690-695 (2008)
27. Wang, F. et al. Deacetylation of FOXO3 by SIRT1 or SIRT2 leads to Skp2- mediated FOXO3 ubiquitination and degradation. Oncogene. 31, 1546-1557 (2012)
28. Draheim, K.M. et al. ARRDC3 suppresses breast cancer progression by negatively regulating integrin beta4. Oncogene. 29, 5032-5047 (2010)
29. Nabhan, J. F., Pan, H. & Lu, Q. Arrestin domain-containing protein 3 recruits the NEDD4 E3 ligase to mediate ubiquitination of the beta2-adrenergic receptor. EMBO Rep. 11, 605-611 (2010)
30. Jones, P. A. & Baylin, S. B. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 3, 415-428 (2002)
31. Heltweg, B. et al. Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Cancer Res. 66, 4368-4377 (2006)
32. McClure, J. M., Wierman, M. B., Maqani, N. & Smith, J. S. Isonicotinamide enhances Sir2 protein-mediated silencing and longevity in yeast by raising intracellular NAD1 concentration. J Biol Chem. 287, 20957-20966 (2012)
33. Lu, S., Simin, K., Khan, A. & Mercurio, A. M. Analysis of integrin beta4 expression in human breast cancer: association with basal-like tumors and prognostic significance. Clin Cancer Res. 14, 1050-1058 (2008)
34. Claing, A. et al. beta-Arrestin-mediated ADP-ribosylation factor 6 activation and beta 2-adrenergic receptor endocytosis. J Biol Chem. 276, 42509-42513 (2001)
35. Barnes, W. G. et al. beta-Arrestin 1 and Galphaq/11 coordinately activate RhoA and stress fiber formation following receptor stimulation. J Biol Chem. 280, 8041-8050 (2005)
36. Kovacs, J. J. et al. Arrestin development: emerging roles for beta-arrestins in developmental signaling pathways. Dev Cell. 17, 443-458 (2009)
37. Miller, W. E. et al. beta-arrestin1 interacts with the catalytic domain of the tyrosine kinase c-SRC. Role of beta-arrestin1-dependent targeting of c-SRC in receptor endocytosis. J Biol Chem. 275, 11312-11319 (2000)
38. Perry, S. J. et al. Targeting of cyclic AMP degradation to beta 2-adrenergic receptors by beta-arrestins. Science. 298, 834-836 (2002)
39. Bonezzi, K. et al. Inhibition of SIRT2 potentiates the anti-motility activity of taxanes: implications for antineoplastic combination therapies. Neoplasia. 14, 846-854 (2012)
40. Peck, B. et al. SIRT inhibitors induce cell death and p53 acetylation through targeting both SIRT1 and SIRT2. Mol Cancer Ther. 9, 844-855 (2010)